Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1983; 1:869-872
© 1983 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jedeikin, R
Right arrow Articles by Zinner, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jedeikin, R
Right arrow Articles by Zinner, A., 3rd

Effect of ouabain on the anterograde effective refractory period of accessory atrioventricular connections in children

R Jedeikin, PC Gillette, A Garson Jr, CB Porter, S Beder, P Baron, and AJ Zinner 3rd

The anterograde effective refractory period of the accessory connection was determined before and after the administration of ouabain (0.015 mg/kg intravenously) during electrophysiologic studies in 21 patients with Wolff-Parkinson-White syndrome. The mean age (+/- standard deviation) was 10 +/- 2 years (range 1 month to 31 years). Each patient had stopped taking all cardiac drugs for more than 36 hours. Determination of the anterograde effective refractory period of the accessory connection was made using the atrial extrastimulus technique. A change in the anterograde refractory period of the accessory connection was defined as an increase or decrease of greater than 10 ms from the value before ouabain administration. The post-ouabain anterograde effective refractory period of the accessory connection increased in 2 (9%) of the 21 patients, decreased in 9 (43%) and was unchanged in 10 (48%). This study demonstrated a decrease in the anterograde effective refractory period of the accessory connection of 43% of patients with Wolff-Parkinson-White syndrome after the administration of ouabain.




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement